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a  b  s  t  r  a  c  t
A  novel  direct  antibodies-free  electrochemical  approach  for acute  myocardial  infarction  (AMI)  diagnosis
has been  developed.  For  this  purpose,  a combination  of  the  electrochemical  assay  of plasma  samples  with
chemometrics  was proposed.  Screen  printed  carbon  electrodes  modiﬁed  with  didodecyldimethylammo-
nium  bromide  were  used  for plasma  charactrerization  by cyclic  (CV)  and  square  wave  voltammetry
and  square  wave  (SWV)  voltammetry.  It was  shown  that  the  cathodic  peak  in  voltammograms  at  about
−250 mV vs.  Ag/AgCl  can  be associated  with  AMI.  In  parallel  tests,  cardiac  myoglobin  and  troponin  I,  the
AMI  biomarkers,  were  determined  in  each  sample  by  RAMP® immunoassay.  The  applicability  of the elec-
trochemical  testing  for  AMI  diagnostics  was  conﬁrmed  by  statistical  methods:  generalized  linear  model
(GLM), linear  discriminant  analysis  (LDA)  and  quadratic  discriminant  analysis  (QDA),  artiﬁcial  neural  net
(multi-layer  perception,  MLP),  and  support  vector  machine  (SVM),  all  of  which  were  created  to  obtain
the “True–False”  distribution  prediction  where  “True”  and  “False”  are,  respectively,  positive  and  negative
decision  about  an  illness  event.
© 2011 Elsevier B.V. All rights reserved.
1. Introduction
AMI  is a part of acute coronary syndrome which is the most
common cause of death all over the world. Classical symptoms of
acute myocardial infarction include sudden chest pain, shortness
of breath, nausea, vomiting, palpitations, sweating, and anxiety
(Mallinson, 2010). However, about a quarter of all the AMI  cases
are “silent” and do not show noticable symptoms. This calls for
the development of reliable and simple methods for AMI  diag-
nostics. At present, the diagnosis of AMI  is based on WHO-criteria
(www.who.int) which involve characteristic chest pain, diagnostic
electrocardiogram (ECG) changes, and elevation of the biochemi-
cal markers in the blood samples. Cardiac troponins (cTn), creatine
kinase-MB (CK-MB), and cardiac myoglobin (cMb) are typical
cardiac markers used for the AMI  diagnostics. New approaches
intensively investigated cover two additional groups of markers,
i.e. (i) inﬂammation markers (C-reactive protein, myeloperoxidase,
placental growth factor, pregnancy-associated plasma protein A)
and (ii) cardiac ischemia markers (heart-type fatty acid binding
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protein, ischemia modiﬁed albumin, b-typed natriuretic peptide)
(Yang and Zhou, 2006; McDonnell et al., 2009).
Three different troponins (Tn) are found in the striated muscle.
They form a complex that regulates the actin–myosin interaction
needed for muscle contraction. TnT and TnI each have two  distinct
isoforms speciﬁc for cardiac and skeletal muscle, respectively. In
contrast, the two isoforms of TnC do not discriminate between car-
diac and skeletal muscle but are speciﬁc for fast-twitch skeletal
muscle or to cardiac and slow-twitch skeletal muscle. Since 2000,
cardiac troponin (cTn) has been declared as a preferred biomarker
for myocardial infarction by the American College of Cardiology and
the European Society of Cardiology due to its high sensitivity and
nearly absolute speciﬁcity (O’Brien, 2008). On the other hand, the
speciﬁcity of troponins has recently been questioned, because other
clinical situations, such as sepsis, hypovolemia and renal failure
may  also cause an increase in troponin level (Jeremias and Gibson,
2005).
CK-MB, speciﬁc for cardiac tissue, is still used for the AMI  diag-
nosis. As total creatine kinase activity, CK-MB typically begins to
rise 4–6 h after the onset of infarction but not more than 12 h after.
An elevated serum CK-MB level is relatively speciﬁc for myocar-
dial injury, particularly in patients with ischemic symptoms when
skeletal muscle damage is not observed. These elevations return
to baseline within 36–48 h against up to 10 days seen for Tn. This
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